Risk reduction In a trial of 17,000 adults, those taking the drug Wegovy were less likely to experience nonfatal heart attacks, nonfatal heart strokes or death due to cardiovascular causes than those taking a placebo
10% 43 , respectively)
Furthermore, the study demonstrated functional clinical benefits: natural killer (NK) cell cytotoxicity, a vital marker of immune system strength, increased more than twofold in the high-dose cohort
Novel Peptide CM 7 Targeted c-met with antitumor activity
Additionally, if gut permeability is indeed increased in ME/CFS patients, microbes and antigens may be able to cross the epithelial barrier into surrounding tissue and blood, potentially crossing the BBB and altering the HPA axis (443)
This finding is particularly noteworthy given that some trials extended to 24 weeks of continuous exposure and included participants with obesity-related comorbidities who might be expected to have higher baseline health risks